Previous 10 | Next 10 |
SILVER SPRING, Md., April 04, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), today announced the Company has filed a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for CanGaroo ® RM Antibacterial Envelope, its next-generation biomateria...
SILVER SPRING, Md., March 31, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it wil...
Aziyo Biologics, Inc. (AZYO) Q4 2021 Earnings Conference Call March 3, 2022, 4:30 PM ET Company Participants Ronald Lloyd – President and Chief Executive Officer Matthew Ferguson – Chief Financial Officer Leigh Salvo – Investor Relations, Gilmartin Group, LLC Conference C...
Aziyo Biologics press release (NASDAQ:AZYO): Q4 GAAP EPS of -$0.82. Revenue of $10.9M. For further details see: Aziyo Biologics GAAP EPS of -$0.82, revenue of $10.9M
SILVER SPRING, Md., March 03, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial re...
SILVER SPRING, Md., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company ...
SILVER SPRING, Md., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plan...
SILVER SPRING, Md., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that members...
SILVER SPRING, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (the “Company”), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announc...
Gainers: Insignia Systems (NASDAQ:ISIG) +106%. Energy Focus (NASDAQ:EFOI) +65%. Virpax (NASDAQ:VRPX) +26%. Aziyo (NASDAQ:AZYO) +26%. Digital World Acquisition (NASDAQ:DWACU) +20%. Digital World Acquisition (NASDAQ:DWAC) +20%. RLX Technology (NYSE:RLX) +20%. The Lovesac (NASDAQ:LOVE) +19%. Pho...
News, Short Squeeze, Breakout and More Instantly...
Aziyo Biologics Inc. Company Name:
AZYO Stock Symbol:
NASDAQ Market:
– Company to begin trading under new ticker symbol “ELUT” – SILVER SPRING, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”) today announced a change of the Company’s name to Elutia Inc. The rebranding ref...
Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket SILVER SPRING, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”...
Negotiating multiple LOIs to divest Orthopedic business CanGaroo ® RM 510(k) resubmission to the FDA remains on track SimpliDerm ® quarterly net sales up 32% year-over-year Successful transfer of Cardiovascular product distribution to LeMaitre Vascular ...